IP Library Granted Patent US 9,278,085
Granted Patent B2
US 9,278,085 · App. 11/710,042 · Granted Mar 8, 2016

Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,278,085
App. No.
11/710,042
Granted
Mar 8, 2016
Kind
B2
Abstract

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Claims (42)

1. A compound of the formula:

where n is an integer from 2-8 inclusive, and each unit is the same or different;

wherein the bonds indicated with dashed lines are single or double;

wherein R 1 , R 2 and R 3 are independently selected from the group consisting of —H, —C 1 -C 5 alkyl, —C 1 -C 5 haloalkyl, —C 2 -C 5 alkenyl, —C 2 -C 5 haloalkenyl, —C 2 -C 5 alkynyl, and —C 2 -C 5 haloalkynyl, and wherein at least one of R 1 , R 2 , and R 3 is independently selected from the group consisting of —C 1 -C 5 alkyl, —C 1 -C 5 haloalkyl, —C 2 -C 5 alkenyl, —C 2 -C 5 haloalkenyl, —C 2 -C 5 alkynyl, and —C 2 -C 5 haloalkynyl; with the proviso that when R 2 is —C 1 -C 5 alkyl and R 1 is —H, then R 3 is not —H;

where R 4 is selected from the group consisting of —H, —OH, —S—R 5 , —F, —Cl, —I, and —NR 5 R 6 ; where X is selected from the group consisting of —H, —NR 7 R 8 , —OR 9 and —(CH 2 ) 2 C(CH 3 ) 2 OH; where R 5 and R 6 are independently selected from the group consisting of —H, —C 1 -C 5 alkyl, —C 3 -C 6 cycloalkyl, —C 1 -C 5 haloalkyl, aryl, heteroaryl, —(C═O)—C 1 -C 8 alkyl, —(C═O)—C 1 -C 8 alkyl-C 6 -C 10 aryl-C 0 -C 8 alkyl, and —(C═O)—C 0 -C 8 alkyl-C 6 -C 10 aryl-C 1 -C 8 alkyl, or where R 5 and R 6 selected from these groups are combined to form a ring;

where R 7 and R 8 are independently selected from the group consisting of —H, —C 1 -C 8 alkyl, —C 1 -C 8 haloalkyl, and —(C═O)—C 1 -C 8 alkyl, or where either one of R 7 and R 8 is independently selected from the group consisting of —(C═O)—C 1 -C 8 haloalkyl; —(C═O)—NH 2 ; —(C═O)—NHC 1 -C 8 alkyl; —(C═O)—NHC 1 -C 8 haloalkyl; —(C═O)—NR 20 R 21 where R 20 is —(CH 2 ) p —, R 21 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 20 and R 21 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 20 and R 21 and the nitrogen atom to which they are attached; —(C═O)—OC 1 -C 8 alkyl; —(C═O)—OC 1 -C 8 haloalkyl; —S(O) 2 C 1 -C 8 alkyl; —S(O) 2 aryl; and —S(O) 2 aralkyl; and where the other of R 7 and R 8 is —H, —C 1 -C 8 alkyl or —C 1 -C 8 haloalkyl or where R 7 and R 8 selected from these groups are combined to form a ring, or where R 7 is —(CH 2 ) p —, R 8 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 7 and R 8 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 7 and R 8 and the nitrogen atom to which they are attached;

where R 9 is independently selected from the group consisting of —H; —C 1 -C 8 alkyl; —C 1 -C 8 haloalkyl; —(C═O)—C 1 -C 8 alkyl; —(C═O)—C 1 -C 8 haloalkyl; —(C═O)—NH 2 ; —(C═O)—NHC 1 -C 8 alkyl; —(C═O)—NHC 1 -C 8 haloalkyl; —(C═O)—NR 20 R 21 where R 20 is —(CH 2 ) p —, R 21 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 20 and R 21 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 20 and R 21 and the nitrogen atom to which they are attached; —(C═O)—OC 1 -C 8 alkyl; —(C═O)—OC 1 -C 8 haloalkyl; —S(O) 2 C 1 -C 8 alkyl; —S(O) 2 aryl; and —S(O) 2 ;

with the provisos that when n=3 and R 4 is —H or —OH, then X is not —H, and that the compound is not

or any stereoisomer, mixture of stereoisomers, or salt thereof.

2. The compound of claim 1 , where R 4 is —H or —OH.

3. The compound of claim 1 , wherein at least two of R 1 , R 2 , and R 3 are independently selected from the group consisting of —C 2 -C 5 alkyl, —C 2 -C 5 haloalkyl, —C 2 -C 5 alkenyl, —C 2 -C 5 haloalkenyl, —C 2 -C 5 alkynyl, and —C 2 -C 5 haloalkynyl.

4. The compound of claim 3 , wherein R 1 , R 2 , and R 3 are independently selected from the group consisting of —C 2 -C 5 alkyl, —C 2 -C 5 haloalkyl, —C 2 -C 5 alkenyl, —C 2 -C 5 haloalkenyl, —C 2 -C 5 alkynyl, and —C 2 -C 5 haloalkynyl.

5. A compound of the formula:

where n is an integer from 1-9 inclusive, and each unit is the same or different;

wherein the bonds indicated with dashed lines are single or double;

wherein R 1 , R 2 and R 3 are independently selected from the group consisting of —H, —C 1 -C 5 alkyl, —C 1 -C 5 haloalkyl, —C 2 -C 5 alkenyl, —C 2 -C 5 haloalkenyl, —C 2 -C 5 alkynyl, and —C 2 -C 5 haloalkynyl, with the proviso that when R 2 is —C 1 -C 5 alkyl and R 1 is —H, then R 3 is not —H; where R 4 is selected from the group consisting of —H, —O—R 5 , —S—R 5 , —F, —Cl, —Br, —I, and —NR 5 R 6 ;

where X is selected from the group consisting of —NR 7 R 8 , —OR 9 and —(CH 2 ) 2 C(CH 3 ) 2 OH;

where R 5 and R 6 are independently selected from the group consisting of —H, —C 1 -C 5 alkyl, —C 3 -C 6 cycloalkyl, —C 1 -C 5 haloalkyl, aryl, heteroaryl, —(C═O)—C 1 -C 8 alkyl, and —(C═O)—C 0 -C 8 alkyl-C 6 -C 10 aryl-C 0 -C 8 alkyl, or where R 5 and R 6 selected from these groups are combined to form a ring;

where R 7 and R 8 are independently selected from the group consisting of —H, —C 1 -C 8 alkyl, —C 1 -C 8 haloalkyl, and —(C═O)—C 1 -C 8 alkyl, or where either one of R 7 and R 8 is independently selected from the group consisting of —(C═O)—C 1 -C 8 haloalkyl; —(C═O)—NH 2 ; —(C═O)—NHC 1 -C 8 alkyl; —(C═O)—NHC 1 -C 8 haloalkyl; —(C═O)—NR 20 R 21 where R 20 is —(CH 2 ) p —, R 21 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 20 and R 21 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 20 and R 21 and the nitrogen atom to which they are attached; —(C═O)—OC 1 -C 8 alkyl; —(C═O)—OC 1 -C 8 haloalkyl; —S(O) 2 C 1 -C 8 alkyl; —S(O) 2 aryl; and —S(O) 2 aralkyl; and where the other of R 7 and R 8 is —H, —C 1 -C 8 alkyl or —C 1 -C 8 haloalkyl or where R 7 and R 8 selected from these groups are combined to form a ring, or where R 7 is —(CH 2 ) p —, R 8 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 7 and R 8 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 7 and R 8 and the nitrogen atom to which they are attached;

where R 9 is independently selected from the group consisting of —H; —C 1 -C 8 alkyl; —C 1 -C 8 haloalkyl; —(C═O)—C 1 -C 8 alkyl; —(C═O)—C 1 -C 8 haloalkyl; —(C═O)—NH 2 , —(C═O)—NHC 1 -C 8 alkyl; —(C═O)—NHC 1 -C 8 haloalkyl; —(C═O)—NR 20 R 21 where R 20 is —(CH 2 ) p —, R 21 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 20 and R 21 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 20 and R 21 and the nitrogen atom to which they are attached; —(C═O)—OC 1 -C 8 alkyl; —(C═O)—OC 1 -C 8 haloalkyl; —S(O) 2 C 1 -C 8 alkyl; —S(O) 2 aryl; and —S(O) 2 ;

with the provisos that when R 1 and R 2 are -OMe and R 3 is -Me, then either R 4 is neither —H nor —OH, or X is neither —OH nor —(CH 2 ) 2 C(CH 3 ) 2 OH, and that the compound is not

or any stereoisomer, mixture of stereoisomers, or salt thereof.

6. The compound of claim 5 , wherein X is —OH or —NH 2 .

7. The compound of claim 6 wherein the compound is of the formula:

or any stereoisomer, mixture of stereoisomers, or salt thereof.

8. The compound of claim 5 wherein X is —(CH 2 ) 2 C(CH 3 ) 2 OH.

9. The compound of claim 8 of the formula:

or any stereoisomer, mixture of stereoisomers, or salt thereof.

10. A compound of the formula:

where n is an integer from 0 to 9 inclusive, and each unit is the same or different;

wherein the bonds indicated with dashed lines are single or double;

wherein R 1 , R 2 and R 3 are independently selected from the group consisting of —H, —C 1 -C 5 alkyl, —C 1 -C 5 haloalkyl, —C 2 -C 5 alkenyl, —C 2 -C 5 haloalkenyl, —C 2 -C 5 alkynyl, and —C 2 -C 5 haloalkynyl, with the proviso that when R 2 is —C 1 -C 5 alkyl and R 1 is —H, then R 3 is not —H;

where R 4 is selected from the group consisting of F, Cl, and I;

where X is selected from the group consisting of —H, —NR 7 R 8 , —OR 9 , and —(CH 2 ) 2 C(CH 3 ) 2 OH;

where R 7 and R 8 are independently selected from the group consisting of —H, —C 1 -C 8 alkyl, —C 1 -C 8 haloalkyl, and —(C═O)—C 1 -C 8 alkyl, or where either one of R 7 and R 8 is independently selected from the group consisting of —(C═O)—C 1 -C 8 haloalkyl; —(C═O)—NH 2 ; —(C═O)—NHC 1 -C 8 alkyl; —(C═O)—NHC 1 -C 8 haloalkyl; —(C═O)—NR 20 R 21 where R 20 is —(CH 2 ) p —, R 21 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 20 and R 21 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 20 and R 21 and the nitrogen atom to which they are attached; —(C═O)—OC 1 -C 8 alkyl; —(C═O)—OC 1 -C 8 haloalkyl; —S(O) 2 C 1 -C 8 alkyl; —S(O) 2 aryl; and —S(O) 2 aralkyl; and where the other of R 7 and R 8 is —H, —C 1 -C 8 alkyl or —C 1 -C 8 haloalkyl or where R 7 and R 8 selected from these groups are combined to form a ring, or where R 7 is —(CH 2 ) p —, R 8 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 7 and R 8 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 7 and R 8 and the nitrogen atom to which they are attached;

where R 9 is independently selected from the group consisting of —H; —C 1 -C 8 alkyl; —C 1 -C 8 haloalkyl; —(C═O)—C 1 -C 8 alkyl; —(C═O)—C 1 -C 8 haloalkyl; —(C═O)—NH 2 ; —(C═O)—NHC 1 -C 8 alkyl; —(C═O)—NHC 1 -C 8 haloalkyl; —(C═O)—NR 20 R 21 where R 20 is —(CH 2 ) p —, R 21 is —(CH 2 ) q —, p and q are independently integers between 0 and 7 inclusive, p+q is between 2 and 7 inclusive, R 20 and R 21 together with the nitrogen atom to which they are attached combine to form a 3- to 8-membered ring, and where another group selected from the group consisting of —NH—, —N(C 1 -C 4 alkyl)-, —O—, and —S— is optionally incorporated in the ring formed by R 20 and R 21 and the nitrogen atom to which they are attached; —(C═O)—OC 1 -C 8 alkyl; —(C═O)—OC 1 -C 8 haloalkyl; —S(O) 2 C 1 -C 8 alkyl; —S(O) 2 aryl; and —S(O) 2 ;

or any stereoisomer, mixture of stereoisomers, or salt thereof.

11. The compound of claim 10 of the formula:

or any stereoisomer, mixture of stereoisomers, or salt thereof.

12. The compound of claim 1 , additionally comprising a pharmaceutically acceptable excipient.

13. The compound of claim 5 , additionally comprising a pharmaceutically acceptable excipient.

14. The compound of claim 10 , additionally comprising a pharmaceutically acceptable excipient.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2019
From: BIOELECTRON TECHNOLOGY CORPORATION
To: PTC THERAPEUTICS, INC.
Reel/Frame 051041/0478 →
CHANGE OF NAME Recorded Feb 8, 2017
From: EDISON PHARMACEUTICALS, INC.
To: BIOELECTRON TECHNOLOGY CORPORATION
Reel/Frame 041660/0644 →
RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS RECORDED AT REEL/FRAME 25572/731 Recorded Jul 11, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: PENWEST PHARMACEUTICALS CO.
Reel/Frame 026571/0792 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Dec 30, 2010
From: PENWEST PHARMACEUTICALS CO.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025572/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2007
From: MILLER, GUY M.; HECHT, SIDNEY M.; JANKOWSKI, ORION D.; WESSON, KIERON E.; MOLLARD, PAUL
To: EDISON PHARMACEUTICALS, INC.
Reel/Frame 019346/0954 →